Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Shinpoong Pharmaceutical / Equity Bottom-Up

<ul>
  <li>
<a href="https://smartkarma.com/entities/shinpoong-pharmaceutical-co-ltd">Shinpoong Pharmaceutical</a> is a South Korean pharmaceutical company transitioning from a generics manufacturer to an R&amp;D-focused entity, highlighted by its antimalarial drug Pyramax and a pipeline focused on cardiovascular and neurological diseases.</li>
  <li>The company has experienced significant financial headwinds, with consistent net losses and negative cash flow over the past three fiscal years, although recent quarterly results in 2025 show a marked improvement towards profitability.</li>
  <li>Future growth hinges on the successful clinical progression and commercialization of its key pipeline asset, Otaplimastat (SP-8203) for acute ischemic stroke, and its ability to expand its global market presence for existing products.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
Shinpoong Pharmaceutical is a South Korean pharmaceutical company transitioning from a generics manufacturer to an R&amp;D-focused entity, highlighted by its antimalarial drug Pyramax and a pipeline focused on cardiovascular and neurological diseases.
  The company has experienced significant financial headwinds, with consistent net losses and negative cash flow over the past three fiscal years, although recent quarterly results in 2025 show a marked improvement towards profitability.
  Future growth hinges on the successful clinical progression and commercialization of its key pipeline asset, Otaplimastat (SP-8203) for acute ischemic stroke, and its ability to expand its global market presence for existing products.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Shinpoong Pharmaceutical (019170 KS) - Nov 2025

South Korea

Shin Poong Pharmaceutical Co., Ltd. manufactures pharmaceutical raw materials and prescription drugs, such as cephalosporin antibiotics, hemostatics, sedative agents, and anti-diabetics.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Primer: Shinpoong Pharmaceutical (019170 KS) - Nov 2025

Shinpoong Pharmaceutical is a South Korean pharmaceutical company transitioning from a generics manufacturer to an R&D-focused entity,...

αSK